SCHEMBL17456285

SCHEMBL17456285

O=C1OCCc2ncn(-c3ccc(F)c(F)c3)c21

nearest known ligand 0.54

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 17/20 0.54
▸ THRB P10828 1/20 0.39
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25584611 0.89 CYP11B2 (0.46) CYP11B2NPC1RAB9A
SCHEMBL17456268 0.82 CYP11B2 (0.52) CYP11B2RAB9A
SCHEMBL25584168 0.82 CYP11B2 (0.49) CYP11B2
SCHEMBL25584157 0.80 CYP11B2 (0.52) CYP11B2
SCHEMBL17456289 0.80 CYP11B2 (0.68) CYP11B2
SCHEMBL20245729 0.79 CYP11B2 (0.46) CYP11B2
SCHEMBL25584589 0.79 CYP11B2 (0.51) CYP11B2
SCHEMBL17456307 0.76 CYP11B2 (0.64) CYP11B2
SCHEMBL17456317 0.76 CYP11B2 (0.69) CYP11B2
SCHEMBL25584166 0.76 CYP11B2 (0.60) CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12263157-B2 Aldosterone synthase inhibitors for treating chronic kidney disease BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-04-01 — — US disclosed
US-20250049763-A1 ALDOSTERONE SYNTHASE INHIBITORS FOR TREATING CHRONIC KIDNEY DISEASE BOEHRINGER INGELHEIM INT (DE) 2025-02-13 — — US disclosed
US-20230181538-A1 ALDOSTERONE SYNTHASE INHIBITORS FOR TREATING CHRONIC KIDNEY DISEASE BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2023-06-15 — — US disclosed
US-20230181538-A1 ALDOSTERONE SYNTHASE INHIBITORS FOR TREATING CHRONIC KIDNEY DISEASE BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2023-06-15 — — US disclosed
US-20230181538-A1 ALDOSTERONE SYNTHASE INHIBITORS FOR TREATING CHRONIC KIDNEY DISEASE BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2023-06-15 — — US disclosed
EP-3172212-B1 ALDOSTERONE SYNTHASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2018-06-13 — — EP disclosed
US-9334285-B2 Aldosterone synthase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-05-10 — — US disclosed
US-9334285-B2 Aldosterone synthase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-05-10 — — US disclosed
US-9334285-B2 Aldosterone synthase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-05-10 — — US disclosed
US-20160024105-A1 ALDOSTERONE SYNTHASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-01-28 — — US disclosed
US-20160024105-A1 ALDOSTERONE SYNTHASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-01-28 — — US disclosed
US-20160024105-A1 ALDOSTERONE SYNTHASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024105-A1 ALDOSTERONE SYNTHASE INHIBITORS CYP11B1, CYP21A2, CYP11B2 CYP11B2 3/4885THRB 1096/4885NPC1 398/4885
US-20250049763-A1 ALDOSTERONE SYNTHASE INHIBITORS FOR TREATING CHRONIC KIDNEY DISEASE SLC5A2, SLC5A1, REN CYP11B2 10/4885THRB 1706/4885NPC1 510/4885
US-20230181538-A1 ALDOSTERONE SYNTHASE INHIBITORS FOR TREATING CHRONIC KIDNEY DISEASE SLC5A2, SLC5A1, REN CYP11B2 10/4885THRB 1363/4885NPC1 616/4885
US-12263157-B2 Aldosterone synthase inhibitors for treating chronic kidney disease SLC5A1, SLC5A2, REN CYP11B2 12/4885THRB 1755/4885NPC1 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback